Treatment of refractory uveitic macular edema with dexamethasone intravitreal implants in a pediatric patient with bilateral granulomatous idiopathic panuveitis: a case report
© Bourgault et al.; licensee Springer. 2013
Received: 29 June 2013
Accepted: 14 October 2013
Published: 22 October 2013
Macular edema is a common complication of uveitis and represents a therapeutic challenge, especially in children. Recently, intravitreal dexamethasone implants have been shown to decrease intraocular inflammation and to control uveitic macular edema in patients with non-infectious intermediate or posterior uveitis.
An 11-year-old boy with bilateral granulomatous idiopathic panuveitis and orbital inflammation experienced macular edema refractory to topical steroids and subcutaneous methotrexate. He was treated with off-label bilateral injections of dexamethasone intravitreal implant. Three months later, his vision had improved from 20/200 in both eyes to 20/30 in the right eye and 20/40 in the left eye. Optical coherence tomography showed complete resolution of the cystoid macular edema and subretinal fluid in both eyes.
This is a rare report of the use of bilateral dexamethasone intravitreal implant in a pediatric patient. The implants achieved complete resolution of the uveitic macular edema with no adverse events 3 months post-implantation.
KeywordsDexamethasone intravitreal implant Ozurdex® Cystoid macular edema Uveitic macular edema Uveitis Panuveitis Pediatric uveitis
The prevalence of pediatric cases within the general uveitis population is estimated to range from 5% to 13.8% [1–3]. The treatment of uveitis in children is challenging due to the lack of verbalization of symptoms, difficult examination, and suboptimal compliance to the recommended treatment . Corticosteroids remain the mainstay of treatment but are associated with unique complications in children especially when used systemically, such as growth retardation [5–7]. Intravitreal triamcinolone has been used to treat uveitic macular edema but is associated with a significant risk of increased intraocular pressure and cataract [8, 9]. A novel dexamethasone intravitreal implant (Ozurdex®, Allergan Inc., Irvine, CA, USA) has been shown to significantly improve intraocular inflammation, visual acuity, and central macular thickness in adults with non-infectious intermediate or posterior uveitis . Recently, control of inflammation and resolution of cystoid macular edema (CME) was achieved with dexamethasone implant in 13 out of 14 eyes of patients with pediatric uveitis . We present a rare case of a child followed for bilateral recalcitrant uveitic macular edema despite systemic immunosuppression who responded to dexamethasone intravitreal implants.
The patient had undergone a diagnostic vitrectomy with intravitreal injection of triamcinolone acetonide in the left eye 3 months after presentation for worsening of macular edema despite treatment with subcutaneous methotrexate for 6 weeks. The vitreous biopsy yielded negative cultures for bacteria, mycobacteria, fungus, and parasites. The central foveal thickness dramatically decreased from 1,002 μm preoperatively to 238 μm with complete resolution of the uveitic macular edema at 1 month after surgery.
The patient did not experience significant uveitic macular edema recurrence requiring local treatment over the next 2 years. Further systemic therapy with infliximab, which was added 11 months after the Ozurdex injections, has achieved excellent control of his uveitis.
CME is a common complication of pediatric uveitis with a prevalence of approximately 30% at 3 years from initial presentation [3, 6]. In a large case series of 527 pediatric uveitis patients, CME was second only to hypotony as the uveitic complication with the most significant visual impact . Our patient demonstrated macular edema that was refractory to topical steroids and immunosuppression with methotrexate but that was exquisitely responsive to vitrectomy and intravitreal triamcinolone acetonide in one eye.
When he experienced a second flare-up of his uveitic macular edema, the newly available Ozurdex® implant was considered because of its duration of action and its stability in vitrectomized eyes. The half-life of intravitreal triamcinolone acetonide is shorter in a vitrectomized eye, its concentration decreasing 1.5 times more rapidly than in a non-vitrectomized eye . On the other hand, Ozurdex® exhibits a vitreous concentration of dexamethasone that is sustained over time to a similar extent in vitrectomized and non-vitrectomized eyes . Moreover, pharmacokinetic and pharmacodynamic data suggest that when injected into the posterior segment, the implant releases dexamethasone into the vitreoretinal tissues for up to 6 months . Three months after the injections, our patient experienced a significant visual acuity improvement and a normalization of his OCT in both eyes. He did not show increased intraocular pressure but posterior subcapsular cataracts started to develop. The methotrexate treatment was replaced by mycophenolate mofetil around the same time that the implants were injected and it may have assisted in the macular edema control. Mycophenolate mofetil takes several weeks to have an effect and probably did not play a significant role in the initial control of the macular edema. However, it possibly helped to keep the macula dry after the effect of the implants wore off.
This case did not only represent a therapeutic challenge, but also a diagnostic one. Tuberculosis was first considered as the etiology of our patient’s uveitis but that hypothesis was later abandoned. Although a strong suspicion for sarcoid-associated uveitis and orbital disease was raised, this diagnosis could not be confirmed despite an extensive work-up including a biopsy of an enlarged lacrimal gland. The etiology was therefore labeled as idiopathic.
In a previous report of the use of the Ozurdex® intravitreal implant for the treatment of uveitis in children, 31% of treated eyes that showed an initial response relapsed within 6 months of their injection, at a median time of 4 months . This finding stresses the importance of concomitant systemic immunosuppressive therapy to achieve long-term control of ocular inflammation. Lowder et al. showed that dexamethasone intravitreal implant was effective in controlling ocular inflammation and had an advantageous safety profile, with less than 10% of treated eyes having an intraocular pressure of 25 mmHg or greater and no significant increased risk of cataract . Nevertheless, they did not study the safety profile of repeated injections. We believe that Ozurdex® has a role in the treatment of pediatric uveitis or its complications, such as macular edema, which are not well controlled with systemic therapy or when compliance with medication may be a problem.
Written informed consent was obtained from the patient’s guardian/parent/next of kin for the publication of this report and any accompanying images.
Cystoid macular edema
Optical coherence tomography.
SB is supported in part by the 'Programme des bourses McLaughlin du doyen de la Faculté de médecine de l’Université Laval’ and the William H. Ross Fellowship in Vitreo-Retinal Excellence. AL is supported in part by the 'Programme des bourses McLaughlin du doyen de la Faculté de médecine de l’Université Laval.’ The authors thank Cheyenne Johnson BNSc, RN, MPH, CCRP for assisting with the literature review and for reviewing the manuscript. Grant was received from Allergan Inc. to support the publication of this study.
- Perkins ES: Pattern of uveitis in children. Br J Ophthalmol 1966, 50: 169–185. 10.1136/bjo.50.4.169PubMed CentralPubMedView Article
- Cunningham ET Jr: Uveitis in children. Ocul Immunol Inflamm 2000, 8: 251–261. 10.1076/ocii.22.214.171.12459PubMedView Article
- Rosenberg KD, Feuer WJ, Davis JL: Ocular complications of pediatric uveitis. Ophthalmology 2004, 111: 2299–2306. 10.1016/j.ophtha.2004.06.014PubMedView Article
- Nagpal A, Leigh JF, Acharya NR: Epidemiology of uveitis in children. Int Ophthalmol Clin 2008, 48: 1–7.PubMedView Article
- Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000, 130: 492–513. 10.1016/S0002-9394(00)00659-0PubMedView Article
- Smith JA, Mackensen F, Sen N, Leigh JF, Watkins AS, Pyatetsky D, Tessler HH, Nussenblatt RB, Rosenbaum JT, Reed GF, Vitale S, Smith JR, Goldstein DA: Epidemiology and course of disease in childhood uveitis. Ophthalmology 2009, 116: 1544–1551. 10.1016/j.ophtha.2009.05.002PubMed CentralPubMedView Article
- McDonough AK, Curtis JR, Saag KG: The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008, 20: 131–137. 10.1097/BOR.0b013e3282f51031PubMedView Article
- Kok H, Lau C, Maycock N, McCluskey P, Lightman S: Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005, 112: 1916–1921.PubMedView Article
- van Kooij B, Rothova A, de Vries P: The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm 2006, 14: 73–85. 10.1080/09273940500545684PubMedView Article
- Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011, 129: 545–553. 10.1001/archophthalmol.2010.339PubMedView Article
- Taylor SR, Tomkins-Netzer O, Joshi L, Morarji J, McLoone E, Lightman S: Dexamethasone implant in pediatric uveitis. Ophthalmology 2012, 119: 2412. 10.1016/j.ophtha.2012.07.025PubMedView Article
- Chin HS, Park TS, Moon YS, Oh JH: Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 2005, 25: 556–560. 10.1097/00006982-200507000-00002PubMedView Article
- Chang-Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, Zhang KM, Kuppermann BD, Robinson MR, Whitcup SM, Welty DF: Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2011, 52: 4605–4609. 10.1167/iovs.10-6387PubMedView Article
- Chang-Lin JE, Attar M, Acheampong A, Robinson MR, Whitcup SM, Kuppermann BD, Welty D: Pharmacokinetics and pharmacodynamics of the sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011, 52: 80–86. 10.1167/iovs.10-5285PubMedView Article
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.